VKTX Stock Recent News

VKTX LATEST HEADLINES

VKTX Stock News Image - prnewswire.com

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO , June 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.  The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.

prnewswire.com 2024 Jun 24
VKTX Stock News Image - zacks.com

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.

zacks.com 2024 Jun 20
VKTX Stock News Image - fool.com

Viking Therapeutics has a few promising drug programs near maturity. It will have to ward off tough competitors to succeed.

fool.com 2024 Jun 18
VKTX Stock News Image - fool.com

Viking Therapeutics has the potential to be a great growth stock. The company, however, faces a lot of competition in the GLP-1 drug market.

fool.com 2024 Jun 15
VKTX Stock News Image - zacks.com

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.

zacks.com 2024 Jun 13
VKTX Stock News Image - zacks.com

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

zacks.com 2024 Jun 13
VKTX Stock News Image - fool.com

Viking Therapeutics just reported (more) positive phase 2 clinical trial results. Though the company's shares dropped, interested investors shouldn't worry.

fool.com 2024 Jun 09
VKTX Stock News Image - zacks.com

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.

zacks.com 2024 Jun 07
VKTX Stock News Image - fool.com

Viking Therapeutics stock took a hit this week in response to a clinical update for its midstage liver disease drug. This pullback seems unwarranted, given the company's pivot to weight loss.

fool.com 2024 Jun 06
VKTX Stock News Image - zacks.com

Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

zacks.com 2024 Jun 05
10 of 50